Head-To-Head Survey: LENZ Therapeutics (NASDAQ:LENZ) & NRx Pharmaceuticals (NASDAQ:NRXP)

NRx Pharmaceuticals (NASDAQ:NRXP) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.

Profitability

This table compares NRx Pharmaceuticals and LENZ Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	-691.81%	N/A	-63.92%
LENZ Therapeutics	-586.74%	-53.39%	-49.14%

Volatility & Risk

NRx Pharmaceuticals has a beta of 2.19, meaning that its share price is 119% more volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500.

Valuation & Earnings

This table compares NRx Pharmaceuticals and LENZ Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23 million	116.87	-$28.62 million	($0.55)	-6.04
LENZ Therapeutics	$19.09 million	6.70	-$82.13 million	($4.09)	-1.00

NRx Pharmaceuticals has higher earnings, but lower revenue than LENZ Therapeutics. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for NRx Pharmaceuticals and LENZ Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	2	0	5	0	2.43
LENZ Therapeutics	1	2	5	0	2.50

NRx Pharmaceuticals currently has a consensus price target of $34.50, suggesting a potential upside of 939.16%. LENZ Therapeutics has a consensus price target of $28.80, suggesting a potential upside of 607.62%. Given NRx Pharmaceuticals’ higher possible upside, equities research analysts plainly believe NRx Pharmaceuticals is more favorable than LENZ Therapeutics.

Insider and Institutional Ownership

4.3% of NRx Pharmaceuticals shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 6.4% of NRx Pharmaceuticals shares are owned by insiders. Comparatively, 8.3% of LENZ Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

LENZ Therapeutics beats NRx Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

About LENZ Therapeutics

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.